Vol 79, No 11 (2021)
Short communication
Published online: 2021-10-11

open access

Page views 7965
Article views/downloads 2319
Get Citation

Connect on Social Media

Connect on Social Media

Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry

Reinhold Kreutz1, Gilbert Deray2, Jürgen Floege3, Marianne Gwechenberger4, Kai Hahn5, Andreas R Luft6, Pontus Persson7, Jan Beyer-Westendorf8
Pubmed: 34643264
Kardiol Pol 2021;79(11):1265-1267.

Abstract

Not available

References

  1. Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019; 74(17): 2204–2215.
  2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
  3. Weir MR, Kreutz R. Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants. Mayo Clin Proc. 2018; 93(10): 1503–1519.
  4. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
  5. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  6. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32(19): 2387–2394.
  7. Steffel J, Collins R, Antz M, et al. External reviewers. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23(10): 1612–1676.
  8. Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015; 65(23): 2481–2493.
  9. Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017; 70(21): 2621–2632.
  10. Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. Kardiologia Polska. 2020; 78(2): 105–116.
  11. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604–612.
  12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31–41.
  13. Collins GS, Le Manach Y. Comparing treatment effects between propensity scores and randomized controlled trials: improving conduct and reporting. Eur Heart J. 2012; 33(15): 1867–1869.
  14. Kreutz R, Camm AJ, Rossing P. Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. Eur Heart J Suppl. 2020; 22(Suppl O): O78–O86.



Polish Heart Journal (Kardiologia Polska)